Illinois SB1773 (104th General Assembly), which would amend the Illinois Controlled Substances Act to classify xylazine as a Class/Schedule III controlled substance and include specific statutory exemptions for certain veterinary/animal-drug and professional uses, advanced procedurally in the Illinois House. The ILGA bill status record shows the bill was placed on the House Calendar for 2nd Reading (Short Debate) on 2026-02-13. This is legislative progress and not enactment; compliance teams should treat the requirements as pending and monitor for passage, signature, and any finalized effective/implementation dates.
An Illinois SB1773 committee amendment (sam003), filed 2025-04-01, provides detailed statutory exemption language (new Section 309.1) stating that, notwithstanding the Schedule/Class III scheduling of xylazine, xylazine is not considered a controlled substance when used/handled under specified conditions (including certain licensed veterinarian use for nonhuman species involving FDA-approved animal drugs, use as an API for manufacturing an FDA-approved animal drug, use by licensed certified euthanasia technicians employed by certified euthanasia agencies, and wildlife biologist fieldwork under indirect veterinarian supervision). Compliance teams should use the amendment text to assess whether current/anticipated xylazine activities would fall under exemptions if SB1773 is enacted.